{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:58:33Z","timestamp":1790773113159,"version":"4.1.0"},"reference-count":5,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"DOI":"10.25259\/ijdvl_579_2025","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T06:53:42Z","timestamp":1752476022000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dupilumab in Chinese patients aged over 60 years with bullous pemphigoid and comorbidities"],"prefix":"10.25259","volume":"0","author":[{"given":"Shiyu","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Hangzhou Third Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hangzhou Third People\u2019s Hospital, Zhejiang Chinese Medical University, Hangzhou, People\u2019s Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"key":"10.25259\/IJDVL_579_2025\/ref-1","doi-asserted-by":"publisher","first-page":"1165106","DOI":"10.3389\/fimmu.2023.1165106","article-title":"Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: A monocentric real-world study","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_579_2025\/ref-2","doi-asserted-by":"publisher","first-page":"888","DOI":"10.25259\/IJDVL_1149_2022","article-title":"Dupilumab as monotherapy for bullous pemphigoid with multiple underlying diseases: A report of two cases","volume":"89","author":"Chen","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_579_2025\/ref-3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ajd.13692","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_579_2025\/ref-4","doi-asserted-by":"publisher","first-page":"738907","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_579_2025\/ref-5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ijdvl.com\/efficacy-and-safety-of-dupilumab-in-chinese-patients-aged-over-60-years-with-bullous-pemphigoid-and-comorbidities\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ijdvl.com\/efficacy-and-safety-of-dupilumab-in-chinese-patients-aged-over-60-years-with-bullous-pemphigoid-and-comorbidities\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:14:57Z","timestamp":1790770497000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijdvl.com\/efficacy-and-safety-of-dupilumab-in-chinese-patients-aged-over-60-years-with-bullous-pemphigoid-and-comorbidities\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":5,"alternative-id":["10.25259\/IJDVL_579_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_579_2025","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"article-number":"1"}}